-  INCLUSION CRITERIA:

               1. Measurable metastatic (stage IV) or unresectable non-small cell lung cancer
                  (including but not limited to squamous cell carcinoma, adenosquamous carcinoma,
                  or adenocarcinomas) with at least one lesion that is resectable for TIL
                  generation. (Note: neuroendocrine tumors are not eligible.)

               2. Patients with 3 or fewer brain metastases that are less than 1 cm in diameter and
                  asymptomatic are eligible. Lesions that have been treated with stereotactic
                  radiosurgery must be clinically stable for 1 month after treatment for the
                  patient to be eligible. Patients with surgically resected brain metastases are
                  eligible.

               3. All patients must have had at least one appropriate first line systemic therapy
                  and progressed.

               4. Clinical performance status of ECOG 0 or 1.

               5. Greater than or equal to 18 years of age and less than or equal to 70 years of
                  age.

               6. Patients of both genders must be willing to practice birth control from the time
                  of enrollment on this study and for four months after treatment.

               7. Willing to sign a durable power of attorney

               8. Able to understand and sign the Informed Consent Document

        I. Hematology:

          -  Absolute neutrophil count greater than 1000/mm3 without support of filgrastim

          -  Normal WBC (> 3000/mm3).

          -  Hemoglobin greater than 8.0 g/dl. Subjects may be transfused to reach this cut-off.

          -  Platelet count greater than 100,000/mm3

             j. Serology:

          -  Seronegative for HIV antibody. (The experimental treatment being evaluated in this
             protocol depends on an intact immune system. Patients who are HIV seropositive can
             have decreased immune competence and thus may be less responsive to the experimental
             treatment and more susceptible to its toxicities.)

          -  Seronegative for active hepatitis B, and seronegative for hepatitis C antibody. If
             hepatitis C antibody test is positive, then patient must be tested for the presence of
             antigen by RTPCR and be HCV RNA negative.

             k. Chemistry:

          -  Serum ALT/AST less than 2.5 times the upper limit of normal.

          -  Serum creatinine less than or equal to 1.6 mg/dl.

          -  Total bilirubin less than or equal to 2 mg/dl, except in patients with Gilbert s
             Syndrome, who must have a total bilirubin less than or equal to 3 mg/dl.

             l.Women of child-bearing potential must have a negative pregnancy test because of the

        potentially dangerous effects of the treatment on the fetus.

        m. More than four weeks must have elapsed since any prior systemic therapy at the time the
        patient receives the preparative regimen, and patients toxicities must have recovered to a
        grade 1 or less. Patients may have undergone minor surgical procedures or local
        radiotherapy within the past 4 weeks.

        n. More than two weeks must have elapsed since any prior palliation for major bronchial
        occlusion or bleeding at the time the patient receives the preparative regimen, and patient
        s toxicities must have recovered to a grade 1 or less.

        o. Subjects must be co-enrolled in protocol 03-C-0277

        EXCLUSION CRITERIA:

          1. Women of child-bearing potential who are pregnant or breastfeeding because of the
             potentially dangerous effects of the treatment on the fetus or infant.

          2. Ongoing need for pharmacological immunosuppression, including steroids

          3. Active systemic infections (e.g.: requiring anti-infective treatment), coagulation
             disorders or any other active or uncompensated major medical illnesses.

          4. Major bronchial occlusion or bleeding not amenable to palliation.

          5. Any form of primary immunodeficiency (such as Severe Combined Immunodeficiency

             Disease and AIDS).

          6. Concurrent opportunistic infections (The experimental treatment being evaluated in
             this protocol depends on an intact immune system. Patients who have decreased immune
             competence may be less responsive to the experimental treatment and more susceptible
             to its toxicities.)

          7. History of severe immediate hypersensitivity reaction to any of the agents used in
             this study.

          8. Any patient known to have an LVEF less than or equal to 45%.

          9. Documented LVEF of less than or equal to 45% tested in patients with:

             -Clinically significant atrial and/or ventricular arrhythmias including but not
             limited to:

             atrial fibrillation, ventricular tachycardia, second or third degree heart block or
             have a history of ischemic heart disease, chest pain

             -Age greater than or equal to 65 years old

         10. Documented FEV1 of less than or equal to 50% predicted in patients with clinical

             symptomatology.

         11. Any of the following will exclude patients from the high-dose aldesleukin arm, but may
             be eligible for the low-dose aldesleukin arm:

               -  Greater than 2 invasive thoracic procedures

               -  Poor exercise tolerance

               -  Greater than 66 years of age

         12. Clinically significant patient history which in the judgment of the Principal
             Investigator would compromise the patient s ability to tolerate high-dose.

         13. Patients who are receiving any other investigational agents.